Navigation Links
Cyntellect Appoints Former BD Biosciences Executive Andre Lubarsky as Director of Sales - North America
Date:11/21/2008

New hire brings over 20 years of commercial life sciences sales experience to Cyntellect

SAN DIEGO, Nov. 21 /PRNewswire/ -- Cyntellect, a privately-held life sciences company leading the development and commercialization of live cell analysis and manipulation systems, announced today that it has appointed Andre Lubarsky as the Company's Director of Sales - North America. Andre will be responsible for the sales of Cyntellect's cell purification and cell health products in the life sciences research market. He joins Cyntellect with an extensive sales and sales management background at leading life sciences companies including BD Biosciences, Applied Imaging and Leica Inc.

"Andre's extensive sales and sales management experience in the life sciences research market, particularly in the cellular bioassay and analysis markets, will accelerate the commercialization of Cyntellect's products for applications in biopharmaceutical cell line development, cell line development for drug discovery and research including key applications utilizing stem cells and primary cells," said Fred Koller, Ph.D., Cyntellect's President and Chief Executive Officer. "We are very pleased to have someone of Andre's experience and customer-focused nature join the Cyntellect commercial team."

Andre comes to Cyntellect from BD Biosciences Bioimaging Systems where he filled the role of Director of Sales - North America. Prior to that, he was National Imaging Sales Manager at McBain Instruments in Chatsworth, CA. Andre joined McBain Instruments from a role as Senior Sales Manager at Applied Imaging in Santa Clara, CA. Andre's prior experience included other executive sales management positions with Leica Inc., Bio-Rad Laboratories and Cambridge Instruments. Andre graduated in Biological Sciences from the University of California - San Diego.

About Cyntellect

Cyntellect, Inc. is a life sciences company committed to revolutionizing the use of living cells in life science research and cellular therapy. The Company combines expertise in high-speed cell imaging and laser-based manipulation to develop products that enable novel cell imaging, purification, and transfection capabilities to enhance the productivity of laboratory research, recombinant protein production, high-content cellular assays, functional genomics and proteomics, and cell purification, including processing of cells for therapeutic transplantation. For additional information please visit the Company's web site at www.cyntellect.com.


'/>"/>
SOURCE Cyntellect, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. University of Florida and Cyntellect Collaborate to Unlock Mysteries of Cancer Stem Cells
2. Cyntellect Launches CellXpress(TM) System to Boost Productivity of Biopharmaceutical Process Development
3. Cyntellect to Collaborate With the Burnham Institute for Medical Research
4. InCode BioPharmaceutics Appoints New President and CEO
5. Sangamo BioSciences Appoints Paul Cleveland to Its Board of Directors and Chair of Audit Committee
6. GeneNews appoints Canadian Colorectal Cancer Advisory Board
7. WuXi PharmaTech Appoints Ying Han to Its Board of Directors
8. TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors
9. Accumetrics Appoints John J. Young, MD Chief Medical Officer
10. Potentia Pharmaceuticals Appoints Johanna M. Seddon, M.D. and Janet Stoltz Sunness, M.D. to Scientific Advisory Board
11. Cynvec LLC(SM) Appoints Former Johnson & Johnson Executive Frank D. Stonebanks as President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only ... Center and will showcase its product’s latest features from June 26 to June ... scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
(Date:6/23/2016)... June 23, 2016 ReportsnReports.com ... report to its pharmaceuticals section with historic and ... and much more. Complete report on ... pages, profiling 15 companies and supported with 261 ... http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . The Global Cell ...
Breaking Biology Technology:
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... RATON, Florida , March 29, 2016 ... or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are ... DNA in ink used in a variety of writing ... theft. Buyers of originally created collectibles from athletes on ... through forensic analysis of the DNA. ...
Breaking Biology News(10 mins):